Improving T cell therapy for better cancer treatment
Next-generation T cell therapy: SMARTER T cells for enhanced and durable anti-tumor immunity
['FUNDING_CAREER'] · UNIV OF NORTH CAROLINA CHAPEL HILL · NIH-11176359
This study is working on improving a type of cancer treatment that uses your own immune cells, called T cells, to help them better fight tumors and survive in tough environments, so patients can have more effective options for battling cancer.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF NORTH CAROLINA CHAPEL HILL (nih funded) |
| Locations | 1 site (CHAPEL HILL, UNITED STATES) |
| Trial ID | NIH-11176359 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing T cell therapy, specifically engineered CD8+ T cells, to improve their ability to infiltrate and survive within tumors. By addressing the challenges posed by the hostile tumor microenvironment, the study aims to develop T cells that can provide a more durable anti-tumor immune response. The approach combines expertise in T cell development, genomic analysis, and protein engineering to create a novel solution for current limitations in adoptive cell therapy. Patients may benefit from more effective cancer treatments that harness their own immune cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors who may benefit from enhanced T cell therapies.
Not a fit: Patients with non-solid tumors or those who do not respond to T cell therapies may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and long-lasting cancer treatments for patients.
How similar studies have performed: Other research has shown promise in enhancing T cell therapies, but this approach aims to address specific challenges that have not been fully resolved.
Where this research is happening
CHAPEL HILL, UNITED STATES
- UNIV OF NORTH CAROLINA CHAPEL HILL — CHAPEL HILL, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHUNG, HOKYUNG KAY — UNIV OF NORTH CAROLINA CHAPEL HILL
- Study coordinator: CHUNG, HOKYUNG KAY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy